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Abstract
Background: To assess the impact of long-term oral nitrate therapy on clinical outcome following percutaneous
coronary intervention (PCI) in patients with type II diabetes.
Methods: The incidence of major adverse cardiovascular events (MACEs) following elective PCI for stable coronary
artery disease was evaluated in 108 patients with type II diabetes (age 64.6 ± 10.5 years, 67.7% men). Major adverse
cardiovascular events were defined as the need for revascularization, non-fatal myocardial infarction or
cardiovascular death. Multivariate Cox regression analysis was used to evaluate the predictive value of MACEs by
clinical characteristics and the prescription of long-term nitrate therapy.
Results: Isosorbide mononitrate (ISMN) was prescribed to 46 patients with an average dose of 44.3 ± 15.2 mg/day.
After a mean follow up of 25.3 ± 25 months, 16 patients developed MACEs. Patients who received ISMN were
more likely to suffer from MACEs (26.1% vs. 6.5%, P = 0.01), mainly driven by a higher rate of acute coronary
syndrome (13.0 vs 0%, P = 0.01). Average daily dose of nitrate and other cardiovascular medication was not
associated with MACEs. Multivariate Cox regression analysis revealed that prescription of only ISMN (Hazard Ratio
3.09, 95% CI 1.10-10.21, P = 0.04) was an independent predictor for the development of MACEs.
Conclusion: Long-term oral nitrate therapy was associated with MACEs following elective coronary artery
revascularization by PCI in patients with type II diabetes.
Keywords: Nitrate, Diabetes, MACEs
Introduction
Elective percutaneous coronary intervention (PCI) is a
common treatment for patients with stable coronary
artery disease and comprises 85% of all PCI procedures
[1,2]. Diabetic patients account for up to one quarter of
patients who undergo PCI each year and experience a
higher rate of post-operative adverse cardiovascular
events than non-diabetics [3].
Organic nitrate remains one of the most frequently
prescribed anti-anginal agents for the treatment of cor-
onary artery disease (CAD), although no long-term ben-
eficial effect has been proven [4]. Previous clinical trials
have suggested that continuous administration of oral
nitrates paradoxically increases adverse cardiac events
following myocardial infarction [5-7]. It is nonetheless
remains unknown whether the use of oral nitrates fol-
lowing elective PCI has a deleterious effect in patients
with diabetes. The objective of this study was to deter-
mine the impact of long-term oral nitrate therapy on
clinical outcome in patients with type II diabetes who
undergo elective PCI for stable CAD.
Methods
Patients
Consecutive patients with type II diabetes and stable
clinical symptoms who underwent successful elective
PCI and coronary stenting for stable CAD between
March 2003 and September 2005 were recruited. All
patients had type II diabetes as defined by the American
Diabetic Association [8], and were prescribed a hypogly-
cemic agent (oral antidiabetic agents or insulin). Patients
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were excluded if they had terminal malignancy, conges-
tive heart failure, incomplete or failed revascularization
(residual stenosis > 50% in any one of the three major
coronary arteries), significant left main CAD > 50% ste-
nosis, recent stroke or acute coronary syndrome in the
past 3 months. There was no restriction in terms of
usage of either bare metal or drug eluting stents.
Study Design
Baseline clinical characteristics including body weight,
height, and routine blood biochemistry were documen-
ted in all patients during their admission for PCI. Left
ventricular ejection fraction (LVEF) was also evaluated
by transthoracic echocardiography before PCI and
patients were categorized as having preserved LVEF
≥50% or impaired LVEF < 50%. Data on medication pre-
scribed before and after PCI were ascertained from the
hospital computer system. Patients prescribed oral
nitrate were given long release isosorbide-5-mononitrate
(ISMN). All patients were followed up regularly in our
clinic every 3-4 months. Data concerning all hospital
admissions and death were retrieved from the hospital
electronic record system. During the study period, no
patients were lost to follow up. The presence of triple
CAD was defined as the presence of lesions in all three
major coronary arteries that were either successfully
revascularized or had < 50% residual stenosis. This
study was approved by the local institutional ethic
committee.
The endpoint of this study was the occurrence of
major adverse cardiovascular events (MACEs) including
(1) the need for targeted vessel revascularization due to
in-stent restenosis, or (2) non-fatal myocardial infarc-
tion, defined as the presence of symptoms consistent
with the World Health Organization criteria [9], asso-
ciated with abnormal levels of necrosis markers (includ-
ing troponin) or diagnostic electrocardiogram changes,
and (3) cardiovascular mortality (sudden cardiac death,
fatal stroke, myocardial infarction and heart failure).
Statistical Analysis
Continuous variables are presented as mean ± 1 stan-
dard deviation. Categorical data are presented as fre-
quencies and percentages. Statistical comparisons were
performed with Mann-Whitney U test or Chi-squared
test, as appropriate. The association between clinical
characteristics, underlying triple vessel disease and car-
diac medication and the risk of MACEs was analyzed
using Cox proportional hazards models. Multivariate
analysis was performed with an enter regression model,
in which each variable with a P value ≤ 0.1 (based on
the univariate analysis) was entered into the model. Cal-
culations were performed using SPSS software (version
15.0). A P value < 0.05 was considered statistically
significant.
Results
Baseline demographics
A total of 280 patients underwent elective PCI and 108
patients who satisfied the inclusion criteria were fol-
lowed up for a mean period of 25.3 ± 25 months. Their
mean age was 64.6 ± 10.5 years and 67.6% were men. In
total, 20 patients (18.5%) required insulin therapy and
the mean HbA1c level was 7.8 ± 2.2%. The body mass
index was 25.7 ± 3.8 kg/m2. Triple vessel disease was
present in 14 patients (11.1%) and 34 (31.5%) had
undergone previous percutaneous intervention. A total
of 20 patients (18.5%) had impaired LVEF < 50%. Beta-
blocker, statin and angiotensin converting enzyme inhi-
bitor or angiotensin receptor blocker was prescribed to
> 80% of patients.
A total of 46 patients received ISMN therapy, pre-
scribed for at least 1 month prior to PCI. The mean
duration of ISMN therapy before PCI was 258.2 ± 169.7
days and the total duration of ISMN therapy before and
after PCI was 816.1 ± 691.7 days. The mean total ISMN
dose received per patient was 38.6 ± 40.7 gm and the
average daily dose was 44.3 ± 15.2 mg/day. The baseline
demographics of patients with and without ISMN ther-
apy are shown in Table 1. There were no significant dif-
ferences in terms of age, conventional cardiovascular
risk factors or use of concomitant medication (P > 0.05).
Patients who received ISMN were nonetheless more
likely to suffer from underlying triple vessel disease
(23.9 vs. 4.8%, P = 0.01).
Major adverse cardiovascular events
The clinical outcomes of the study population are sum-
marized in Table 2. Overall, 16 patients (14.8%) devel-
oped MACEs and all-cause mortality was 4.6%. Among
patients with MACEs, 7 developed in-stent restenosis
that required repeat revascularization (presented with
crescendo angina) and 6 were hospitalized for non-fatal
myocardial infarction. Cardiovascular death occurred in
3 (sudden death in 1 patient and fatal stroke in 2).
Patients who received ISMN were more likely to suffer
from MACEs (26.1 vs. 6.5%, P < 0.01), mainly driven by
a higher rate of non-fatal myocardial infarction (13 vs.
0% P < 0.01) (Table 2). There were no differences in
occurrence of in-stent restenosis, cardiovascular mortal-
ity or all-cause mortality between patients with and
without ISMN therapy.
The MACEs and all-cause mortality-free survival
curves of patients with and without ISMN therapy are
shown in Figure 1 and 2, respectively. During a follow
up of over 40 months, the cumulative incidence of
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MACEs was significantly higher in patients with ISMN
compared with those without (log-rank test P < 0.01),
although all-cause mortality did not differ. The predic-
tive value of clinical characteristics and medication on
MACEs was analyzed by Cox proportional hazards ana-
lysis (Table 3). Univariate analysis revealed that age and
ISMN were predictors of MACEs. Multivariate analysis
demonstrated that only the use of ISMN independently
predicted MACEs, not age, creatinine level or triple ves-
sel disease.
Discusssion
The present results demonstrate that ISMN therapy fol-
lowing elective PCI for stable CAD in patients with type
II diabetes is associated with an increased risk of
MACEs, mainly driven by an increased risk of non-fatal
myocardial infarction. The average dose and total
amount of ISMN exposure were nonetheless not asso-
ciated with the likelihood of developing MACEs.
Previous large trials including the ISIS-4 [10] and
GISSI-3 [11] trials have failed to demonstrate any
Table 1 Baseline characteristics between patients with and without ISMN
Variable Without ISMN (n = 62) With ISMN (n = 46) P value
Baseline Demographics
Age, years 64.3 ± 10.1 65.0 ± 11.1 0.75
Male, n (%) 42(67.7) 31(86.1) 1.0
Body mass index, kg/m2 26.3 ± 3.9 25.0 ± 3.6 0.09
Hypertension, n (%) 15(24.2) 5(10.9) 0.09
Smoking, n (%) 29(46.8) 23(50.0) 0.70
Insulin therapy, n (%) 13(21.0) 7(15.2) 0.62
Creatinine, mmol/L 141.1 ± 137.4 128.8 ± 91.9 0.59
HbA1c, % 7.8 ± 2.6 7.8 ± 1.4 0.92
Total cholesterol, mmol/L 4.4 ± 1.0 4.5 ± 1.3 0.88
Triglyceride, mmol/L 1.9 ± 1.6 2.1 ± 4.0 0.76
HDL cholesterol, mmol/L 1.1 ± 0.2 1.2 ± 0.2 0.18
LDL cholesterol, mmol/L 2.6 ± 0.9 2.5 ± .7 0.76
Triple vessel disease, n (%) 3(4.8) 11(23.9) *0.01
Prior myocardial infarction, n (%) 15(24.2) 18(39.1) 0.14
Prior PCI, n (%) 17(27.4) 18(39.1) 0.21
Drug eluting stent, n (%) 43(69.4) 31(67.4) 0.84
Impaired LVEF < 50%, n(%) 13(21.0) 7(15.2) 0.62
Medications after PCI
Beta blocker, n (%) 50(80.6) 38(82.6) 1.0
Calcium channel blocker, n (%) 43(69.4) 29(63.0) 0.40
Statin, n (%) 54(87.1) 41(89.1) 1.0
ACEI/ARB, n (%) 53(85.5) 39(84.8) 0.77
Aldosterone blocker, n (%) 6(9.7) 1(2.2) 0.14
Abbreviation: ACEI = Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; BMI = Body mass inex, HDL = High density lipoprotein; ISMN =
Isosorbide-5-monitrate; LDL = Low density lipoprotein; LVEF = Left ventricular ejection fraction; PCI = Percutaneous coronary intervention;
*: P < 0.05.
Table 2 Duration of follow up and incidence of MACE in patients with and without ISMN
All (n = 108 ) Without ISMN (n = 62) With ISMN (n = 46 ) P value
Duration of Follow-up (months) 25.3 ± 25 26.2 ± 10.8 24.1 ± 13.5 0.39
MACE, n (%) 16 (14.8) 4 (6.5) 12 (26.1) * < 0.01
Cardiovascular mortality, n (%) 3 (2.8) 2 (3.2) 1 (2.2) 1.00
Non-fatal myocardial infarction, n (%) 6 (5.5) 0 (0) 6 (13.0) * < 0.01
In-stent restenosis, n (%) 7 (6.5) 2 (3.2) 5 (10.9) 0.13
All cause mortality, n (%) 5 (4.6) 3 (4.8) 2 (4.3) 1.00
Abbreviation: Similar to Table 1, MACE: Major adverse cardiovascular events.
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beneficial effect of nitrate therapy in post myocardial
infarction patients. A recent study of 1000 diabetic
patients with acute myocardial infarction revealed that
early revascularization and treatment with angiotensin
converting enzyme inhibitors, angiotensin II receptor
blocker, and aspirin, not nitrates, are associated with
improved survival [12]. Previous retrospective studies
have also demonstrated that chronic oral nitrate therapy
may have a detrimental effect on the long-term outcome
for patients with CAD [6,7]. In a study by Nakamura
and colleagues, the use of oral nitrate therapy was asso-
ciated with all-cause mortality in 2821 post myocardial
infarction patients [7]. In another study of 1002 myocar-
dial infarction patients randomly assigned to receive or
not receive oral nitrate therapy, oral nitrate therapy was
associated with adverse cardiac events (fatal or non-fatal
recurrent myocardial infarction, congestive heart failure
and sudden death). This adverse association has also
been found in a prospective open label randomized trial
in patients with healed myocardial infarction: patients
who received oral nitrate therapy had a significantly
higher rate of adverse cardiac events (6.6 vs. 3.1%, p <
0.05) after 102 months of follow up than those who did
not [5]. Our results demonstrate that oral nitrate ther-
apy in diabetic patients who undergo elective PCI is
associated with adverse cardiovascular events, mainly
driven by a higher incidence of non-fatal myocardial
infarction. This raises concern about the potential
adverse effects of oral nitrate therapy in patients with
underlying ischemic heart disease, in particular those
with type II diabetes. The recent advent of spinal cord
stimulation and enhanced external counterpulsation
may offer additional treatment options for patients with
refractory angina [13].
Although the use of oral nitrate therapy may be asso-
ciated with an adverse cardiovascular outcome, the
underlying mechanism, particularly in diabetic patients,
remains unclear. One of the major limitations of long-
term oral nitrate treatment is the rapid diminution of its
hemodynamic and anti-ischemic effects as a result of
nitrate tolerance. Recent studies have also demonstrated
that sustained nitrate therapy is associated with an
increased production of reactive oxygen species (ROS) by
uncoupling of endothelial nitrate oxide synthase and acti-
vation of protein kinase C [14-16]. In addition, hypergly-
caemia may cause vascular damage that is mediated
through an increased oxidative stress with the generation
of ROS, such as superoxide (O2
-), hydroxyl (OH) and
peroxyl (RO2)[17-19]. The amplified oxidative stress in
patients with type II diabetes and chronic nitrate therapy
may aggravate the harmful vascular effects, and contri-
bute to an increased adverse long-term clinical outcome.
Another possible explanation of our findings is that the
increased platelet aggregating activity in patients with
CAD [20] and diabetes [21] following nitrate administra-
tion may subsequently lead to higher rates of cardiovas-
cular events. The presence of diabetes and nitrate
therapy has recently been shown to be associated with
residual platelet reactivity in patients on clopidogrel ther-
apy [22]. This evidence further supports our observation
that chronic nitrate therapy may have a detrimental effect
in type II diabetic patients with established CAD.
A limitation of our study was its retrospective nature:
a randomized, placebo-controlled trial would be prefer-
able. Prescription of medication was at the discretion of
individual physicians and the rationale could not be
easily qualified from patients’ records. Although patients
prescribed long term nitrate therapy were likely a group
of patients with more angina symptoms (reflecting
worse coronary disease), the independent predictive
effect of MACEs persisted in such patients despite mul-
tivariate adjustment for underlying triple vessel disease.
In addition, a significant proportion of diabetic patients
may remain asymptomatic due to underlying silent myo-
cardial ischemia. Thus symptom-driven prescription of
oral nitrates may not allow accurate identification of
diabetic patients with underlying myocardial ischemia. A
study involving 310 diabetic patients who underwent
coronary angiogram with or without revascularization
has demonstrated that asymptomatic diabetic patients
Figure 1 Kaplan-Meier curve for free from major adverse
cardiovascular events (MACEs) in patients with and without
long-term oral nitrate therapy.
Figure 2 Kaplan-Meier curve for free from all-cause mortality
in patients with and without long-term oral nitrate therapy.
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have a higher cardiac death risk (26.4 vs. 8.8%; P <
0.001) compared with well-matched symptomatic dia-
betic patients during a 5 year follow up [23]. We believe
that diabetic patients using oral nitrate may not necessa-
rily represent an excessive higher risk subgroup. Lastly,
the small study population may not allow the identifica-
tion of other potential variables (for example triple ves-
sel disease) that could be associated with MACEs.
Conclusion
The present study demonstrated that long-term oral
nitrate therapy is associated with MACEs following elec-
tive PCI for stable coronary artery disease in type II dia-
betic patients. Although a causal relationship could not
be established due to the retrospective design, we
believe that our results provide the rationale for a future
randomized trial to validate this observation.
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